PCRX · Pacira BioSciences Inc
United States · RS rating 98 · As of 2026-11-03
| Price | 36.39 USD |
|---|---|
| 1-day change | -0.0% |
| RS rating (overall / 1M / 3M / 12M) | 98 / 98 / 95 / 90 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 56 / 77 / 50 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -66.7% |
| Sales growth Q/Q | +9.7% |
| Distance from 52-week high | +0.1% |
| Market cap (USD) | $1.1B |